A Review: Epidemiology, Pathogenesis and Prospect in Developing Vaccines for Novel Coronavirus (COVID-19)

Overview

Journal Indian J Tuberc

Publisher Elsevier

Specialty Infectious Diseases

Date 2021 Mar 1

PMID 33641858

Authors

Pratibha Gupta

Affiliations

Soon will be listed here.

Abstract

In December 2019, a large number of coronavirus cases were emerged in Wuhan, Hubei Province, China and rapidly spread to different countries and territories around the world within four months. The World Health Organization (WHO) declared this outbreak as a global health emergency. The spread of COVID-19 over globe is highly contagious; they transmitted from person-to-person through small droplets of infected person. Many diagnosis and treatment methods have been implemented to reduce and control the outbreak. Efforts have been made to develop coronavirus vaccine against S protein or spike glycoprotein of coronavirus. COVID-19 outbreak will affect the Gross Domestic Product (GDP) of the world. At the time of preparing manuscript, total number of active cases reaches to more than 8.9 million and confirmed death reaches to approx. 4.6 lakh. This article highlights the ongoing research and advances in designing vaccine and therapeutics against COVID-19 and also focusing on the epidemiology, transmission, future direction and control the spread of infectious diseases.

References

Jiang S, He Y, Liu S . SARS vaccine development. Emerg Infect Dis. 2005; 11(7):1016-20. PMC: 3371787. DOI: 10.3201/1107.050219. View

Lu H . Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020; 14(1):69-71. DOI: 10.5582/bst.2020.01020. View

Rajendran K, Krishnasamy N, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A . Convalescent plasma transfusion for the treatment of COVID-19: Systematic review. J Med Virol. 2020; 92(9):1475-1483. PMC: 7267113. DOI: 10.1002/jmv.25961. View

Li G, De Clercq E . Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020; 19(3):149-150. DOI: 10.1038/d41573-020-00016-0. View

Hindson J . COVID-19: faecal-oral transmission?. Nat Rev Gastroenterol Hepatol. 2020; 17(5):259. PMC: 7095230. DOI: 10.1038/s41575-020-0295-7. View

Carlos W, Dela Cruz C, Cao B, Pasnick S, Jamil S . Novel Wuhan (2019-nCoV) Coronavirus. Am J Respir Crit Care Med. 2020; 201(4):P7-P8. DOI: 10.1164/rccm.2014P7. View

Okba N, Muller M, Li W, Wang C, GeurtsvanKessel C, Corman V . Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients. Emerg Infect Dis. 2020; 26(7):1478-1488. PMC: 7323511. DOI: 10.3201/eid2607.200841. View

Lei J, Li J, Li X, Qi X . CT Imaging of the 2019 Novel Coronavirus (2019-nCoV) Pneumonia. Radiology. 2020; 295(1):18. PMC: 7194019. DOI: 10.1148/radiol.2020200236. View

Forni D, Cagliani R, Clerici M, Sironi M . Molecular Evolution of Human Coronavirus Genomes. Trends Microbiol. 2016; 25(1):35-48. PMC: 7111218. DOI: 10.1016/j.tim.2016.09.001. View

10.

Gupta N, Praharaj I, Bhatnagar T, Thangaraj J, Giri S, Chauhan H . Severe acute respiratory illness surveillance for coronavirus disease 2019, India, 2020. Indian J Med Res. 2020; 151(2 & 3):236-240. PMC: 7357403. DOI: 10.4103/ijmr.IJMR_1035_20. View

11.

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y . Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020; 382(13):1199-1207. PMC: 7121484. DOI: 10.1056/NEJMoa2001316. View

12.

Chan J, Kok K, Zhu Z, Chu H, To K, Yuan S . Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020; 9(1):221-236. PMC: 7067204. DOI: 10.1080/22221751.2020.1719902. View

13.

Widjaja I, Wang C, van Haperen R, Gutierrez-Alvarez J, van Dieren B, Okba N . Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein. Emerg Microbes Infect. 2019; 8(1):516-530. PMC: 6455120. DOI: 10.1080/22221751.2019.1597644. View

14.

Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P . In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020; 71(15):732-739. PMC: 7108130. DOI: 10.1093/cid/ciaa237. View

15.

Li H, Wang Y, Xu J, Cao B . [Potential antiviral therapeutics for 2019 Novel Coronavirus]. Zhonghua Jie He He Hu Xi Za Zhi. 2020; 43(0):E002. DOI: 10.3760/cma.j.issn.1001-0939.2020.0002. View

16.

Singhal T . A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr. 2020; 87(4):281-286. PMC: 7090728. DOI: 10.1007/s12098-020-03263-6. View

17.

Phan L, Nguyen T, Luong Q, Nguyen T, Nguyen H, Le H . Importation and Human-to-Human Transmission of a Novel Coronavirus in Vietnam. N Engl J Med. 2020; 382(9):872-874. PMC: 7121428. DOI: 10.1056/NEJMc2001272. View

18.

Lu H, Stratton C, Tang Y . Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J Med Virol. 2020; 92(4):401-402. PMC: 7166628. DOI: 10.1002/jmv.25678. View

19.

Ji W, Wang W, Zhao X, Zai J, Li X . Cross-species transmission of the newly identified coronavirus 2019-nCoV. J Med Virol. 2020; 92(4):433-440. PMC: 7138088. DOI: 10.1002/jmv.25682. View

20.

Du L, He Y, Zhou Y, Liu S, Zheng B, Jiang S . The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009; 7(3):226-36. PMC: 2750777. DOI: 10.1038/nrmicro2090. View